Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study

PURPOSE: The treatment of hepatocellular carcinoma (HCC) patients with high-risk features (Vp4, and/or tumor occupancy≥50%) has not been standardized and has poor outcomes. The present study aimed to assess the safety, efficacy, and prognostic impact of lenvatinib, hepatic arterial infusion chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Xu, Wu, Huiyong, Ning, Shangkun, Li, Xinge, Xie, Yinfa, Shao, Wenbo, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493101/
https://www.ncbi.nlm.nih.gov/pubmed/37701565
http://dx.doi.org/10.2147/JHC.S418387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493101/
https://www.ncbi.nlm.nih.gov/pubmed/37701565
http://dx.doi.org/10.2147/JHC.S418387

Ejemplares similares